What is GNFT's current stock price?

GNFT (Genfit S.A.) is currently trading at $8.95 with a market cap of $445.7M.

What sector is Genfit S.A. in?

Genfit S.A. (GNFT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GNFT a good stock to buy?

Analysts have a Buy consensus on GNFT with a price target of $13.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GNFT Genfit S.A.

Healthcare

$8.95+4.07%ClosedMarket Cap: $445.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-18.26

P/S

6.43

EV/EBITDA

-79.83

DCF Value

$-58.51

FCF Yield

-6.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

26.0%

Operating Margin

-84.3%

Net Margin

-127.4%

ROE

-596.4%

ROA

-54.4%

ROIC

-41.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$35.5M	$-10.0M	$—
Q4 null	$5.9M	$-28.8M	$—
FY null	$67.0M	$1.5M	$—
Q2 null	$61.1M	$30.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$13.00

Target (Median)

$13.00

Target Range

$13.00 - $13.00

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-09-24

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.87

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Peers

IVA

SLS